A carregar...
Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
# Background Further research is needed to determine real-world costs of first-line (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), modified FFX (mFFX), and gemcitabine with nab-paclitaxel (GnP). # Objectives To describe healthcare costs by treatment reg...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Columbia Data Analytics, LLC
2025-08-01
|
| Colecção: | Journal of Health Economics and Outcomes Research |
| Acesso em linha: | https://doi.org/10.36469/001c.142403 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|